The TCR-based therapy market is projected to grow at an annualized rate of 51%

Given the recent approval of a TCR-based therapy, industry stakeholders have initiated several R&D efforts focused on evaluating the potential of such therapy candidates against various disease indications

Roots Analysis has announced the addition of “Global TCR-based Therapy Market (2nd Edition), 2022-2035” report to its list of offerings.
Modified T-cell receptor therapy (TCR therapy) is an emerging class of adoptive therapy that employs genetically modified lymphocytes to target specific tumor markers. Growing burden and unaddressed complex treatment needs of cancer patients have paved the way for more effective, safe and versatile alternatives, such as TCR therapies. Driven by Kimmtrak® approval, promising development pipeline and encouraging clinical trial results, the TCR-based therapy market is anticipated to witness significant growth in the mid to long-term

Key Market Insights
Over 190 TCR-based therapies are currently approved / under development
Close to 45% of the aforementioned candidates are being evaluated in clinical trials (phase I and above), while 30% of them are in preclinical stage of development. More than 90% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature. Further, NY-ESO-1 and MAGE have emerged as the most popular target antigens.

More than 7,000 patients have been enrolled in nearly 110 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased over the last five years. Of the total number of trials, close to 65% are active and still recruiting patients, while close to 26% have already been completed.

Partnership activity within this domain has grown at a CAGR of 27%, between 2015 and 2021
More than 70 agreements have been inked in the last 5 years. Majority of partnership deals signed within this domain were R&D agreements (26%), licensing agreements (21%), and product development and commercialization agreements (16%).

Over 11.2 USD billion has been invested by both private and public investors in this domain, since 2007
Specifically, in 2020 and 2021, industry players raised over USD 2.7 billion. In addition, majority (39%) of the companies primarily received funding through venture capital rounds. Further, around 70% of the total funding instances were reported by players headquartered in the US.

More than 70 patents have been filed / published related to the TCR-based therapies
Close to 85% of the filed / published patents were patent applications, while around 15% were granted patents and others. Of the total granted applications, close to 45% were filed in North America and Europe.

The market is anticipated to grow at a CAGR of 51%, during the period 2022-2035
In 2035, close to 60% of the market revenues are expected to be generated from sales of therapeutics intended for Nasopharyngeal Carcinoma and Multiple Myeloma. Further, therapies targeting for NY-ESO-1 are expected to occupy a larger share (~50%) of the overall market in 2035.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/tcr-based-th

Key Questions Answered
 What is the growth rate of TCR-based therapy market?
 Which region has the highest growth rate in the TCR-based Therapies market?
 Who are the leading industry and non-industry players in this market?
 How many players are developing TCR-based Therapies?
 Which target indication covers the largest TCR-based therapy market share?
 What is the partnership and collaboration trend in the TCR-based therapy domain?
 What is the current IP landscape of TCR-based therapies market?

The financial opportunity within the TCR-based therapies market has been analyzed across the following segments:
 Target Indication(s)
 Nasopharyngeal Carcinoma
 Multiple Myeloma
 Head and Neck Carcinoma
 Sarcoma, Melanoma
 Acute Myeloid Leukemia
 Lung Cancer
 Ovarian Cancer
 Merkel Cell Cancer

 Target Antigen
 NY-ESO-1
 EBV
 gp100
 Others

 Key Geographical Regions
 North America
 Europe
 Asia Pacific
 Latin America
 Middle East and North Africa
 Rest of the World

The report features inputs from eminent industry stakeholders, according to whom, T-cell immunotherapies are expected to be the next big step in cancer immunotherapy. The report includes detailed transcripts of discussions held with the following experts:
 Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
 Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
 Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
 Miguel Forte (Former Chief Operating Officer, TxCell)

The report includes brief profiles of key players (listed below); each profile features an overview of the company, details related to its financial information (if available), details about TCR-based product(s), such as information on type of therapy and current development status, information on technology portfolio (if available), recent developments related to TCR-based therapies and manufacturing capabilities of the players.
 Adaptimmune Therapeutics
 Alaunos Therapeutics
 Bristol Myers Squibb
 Cellular Biomedicine Group
 Gilead Sciences
 GlaxoSmithKline
 Immatics
 Immunocore
 Lion TCR
 Takara Bio
 Zelluna Immunotherapy

For additional details, please visit https://www.rootsanalysis.com/....reports/tcr-based-th or email [email protected]
You may also be interested in the following titles:
1. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (6th Edition), 2022- 2035
2. mRNA Therapeutics and mRNA Vaccines Market (2nd Edition), 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.


Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]

Need CUSTOM SOFTWARE DEVELOPMENT For Your Business?
For More Information:
Visit: wps.asia
Contact Us: 040-43460111

#wps#wpsdesigning#webdesigning#webdevelopment#wpsgroupofcompanies#webengineers#wpscompany.

Satta online game 2023 | Win a Prize
https://sattakingm.in/
https://sattakingg.in/

The Satta Online Game 2023 is the latest in a line of exciting and thrilling online betting games. It allows users to enjoy the excitement of a variety of sporting events and also to win money while doing so. However, it is important to note that there are a number of factors that need to be taken into consideration before signing up and playing the Matka Result game. These factors include the legality of the game and the security of the website.

Medilift Air Ambulance provides the most effective mode of patient transport service with all medical needs while shifting hours. So our Air Ambulance Service is the most demanded in all over the worldwide.

More@ https://www.medilift.in/

#airambulance #mediliftairambulance #patientrescueservices #cardiacambulance #ventilatorambulance #medilift #railambulance #trainambulance #ambulance #emergency #emergencyservices #emergencyresponse #airambulanceserviceinpatna #airambulanceinpatna #airambulancefrompatna #airambulanceserviceinranchi #airambulanceinranchi #airambulancefromranchi

What is The Best Way to Pick an Altcoin? | #crypto Coin Development Company

The liposome development and manufacturing services market is anticipated to grow at a CAGR of nearly 10% till 2035, claims Roots Analysis

Driven by the development of advanced methods for preparation and characterization of liposomes, and the application of these molecules in therapeutics and diagnostics, the demand for liposomes is expected to rise in the coming years.Roots Analysis has announced the addition of “Liposome Manufacturing Market, 2022-2035” report to its list of offerings.

Despite the growing interest in liposome-based therapeutics and diagnostics, the development and manufacturing of liposomes is associated with several challenges, including complex manufacturing processes, huge capital investments, inadequate clinical grade production and GMP compliant industrial scale-up, lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. In order to deal with the aforementioned challenges, a number of pharmaceutical companies have demonstrated the preference to outsource their respective liposome development and manufacturing operations to specialized service providers.

Key Market Insights

More than 70 companies are currently offering services related to liposome development and manufacturing, globally
Majority (74%) of the service providers offer formulation development services for liposomes. This is followed by players offering analytical method development (65%), liposome contract manufacturing (64%), and process development (61%) services.

Close to 6,100 articles focused on liposomes, have been published in reputed scientific journals, since 2017
More than 50% of the articles focused on liposomes were published post-2019. Popular journals that have published multiple articles include International Journal of Pharmaceutics, Journal of Controlled Release, and Pharmaceutics.

More than 800 clinical trials have been registered for the evaluation of liposome-based therapeutics, worldwide
The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 17%, during the period 2017-2021. Of the total number of trials registered, 60% have already been completed, while 26% of the studies are actively recruiting participants.

Nearly 700 patents related to liposomes have been filed / granted, since 2017
Owing to the increase in research and development efforts led by several industry and non-industry players engaged in this domain, close to 55% of patent applications have been filed post-2016. It is worth noting that 61% patents related to liposomes were filed / granted in the US alone.

Over 110 global events related to liposomes were organized in the past couple of years
Majority (63%) of the events related to liposomes, were organized virtually in order to comply with the guidelines in the ongoing COVID-19 pandemic. Further, the agendas of the events organized post-2020 include discussions on the applications, and recent advancements in technologies associated with liposomes.

Go / No-Go framework can be used to assist players in the crucial outsourcing decision-making process
The framework enables evaluation of the current capabilities of liposome-based therapeutic developers, based on 4+ parameters, including trial phase, target therapeutic area, location of trial(s), patient enrollment and willingness to outsource.

North America is anticipated to capture over 40% of the global market share for liposome development and manufacturing services, by 2035
In terms of type of product formulation, the therapeutic formulations of liposomes (71%) are anticipated to capture the highest share, this trend is unlikely to change in the foreseen future. Further, based on end users, majority of the revenue share (76%) of the overall market is likely to be driven by pharmaceutical and biotechnology industry, by 2035.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/....reports/liposome-man

Key Questions Answered
 Who are the key players offering liposome development and manufacturing services?
 What is the evolving trend of publications focused on liposomes?
 How many patents, related to liposomes, have been filed / granted in the past few years?
 Which companies are actively involved in conducting clinical trials for liposomes?
 What are the key agenda items being discussed in various global events / conferences related to liposomes?
 Which factors are likely to influence the decision of liposome manufacturing being done in-house or outsourced?
 How is the current and future market opportunity related to liposome development and manufacturing services, likely to be distributed across key market segments?

The financial opportunity within the liposome development and manufacturing services market has been analyzed across the following segments:
 Type of Product Formulation
 Therapeutic
 Nutraceutical

 Scale of Operation
 Discovery / Research
 Preclinical
 Clinical
 Commercial

 End User
 Pharmaceutical and Biotechnology Industry
 Cosmetic Industry
 Food Industry
 Agricultural Industry
 Academics
 Other Industries

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Middle East and North Africa
 Latin America

The research also includes detailed profiles of the key players (listed below) offering services for liposome development and manufacturing; each profile features an overview of the company, its financial information (if available), details on service portfolio, recent developments and an informed future outlook.
 Baxter BioPharma Solutions
 Charles River Laboratories
 Evonik
 Fresenius Kabi
 Fujifilm
 GEA
 Intertek

For additional details, please visit
https://www.rootsanalysis.com/....reports/liposome-man
or email [email protected]

You may also be interested in the following titles:
1. Biologics Fill Finish Services Market (3rd Edition), 2022-2035
2. Bioavailability Enhancement Technologies and Services Market, 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]

Email Marketing A Cost Effective Way To Reaching Out Your Customers.
visit our site: https://www.wpssms.com
Call Us : 040-43460111
Register Now : https://login.wpslab.in/authentication/register
#promotional, #transacrional,#email_marketing,#voice_sms, #otp_number, #toll_free_number, #virtualnumber #sms #email #smsprovider #smsmarketing #emailmarketing #smsupermalls #digitalmarketing #marketing #socialmediamarketing #socialmedia
#business #marketingdigital #seo #branding #instagram #onlinemarketing #advertising #digital #entrepreneur #contentmarketing #marketingstrategy #digitalmarketingagency #marketingtips

Direct Contact With The Seller Or Buyer For Your Products
Visit : http://www.businessport.co.in/
Call : 040-43460111
#contentmarketingservices #digitalmarketingtips #digitalmarketing #contentmarketing #seo #blogging #marketing #branding #marketingtips #marketingtipsforbusiness #startup #b2bmarketing